The Oncology Clinic Companion is an educational initiative for the entire cancer care team.
Joined April 2018
- Tweets716
- Following238
- Followers267
- Likes1.7K
Pinned Tweet
Delighted to see EIOCCs #MedEd initiative appear in @JECME! Feasibility of Integrating a Mobile Decision-Support App into a Multicomponent CME Initiative: Developing Clinician Competence at the Point of Care:bit.ly/3jDOyXT @EuropeanCME @cpdcontent @ONCOassist #ImmunoOnc
Delighted to be the CME partner for this important launch during #ASCO22
We are pleased to announce the launch of our new NSCLC ONCOdriver Therapy Tool. This tool integrates guidelines on testing & treatment for driver mutations in NSCLC, beginning with #ALK and #ROS1. Find CME-certified companion resources at bit.ly/NSCLC_ONCOdriver #OncoAlert
ALT NSCLC ONCOdriver therapy tool
Oncology Clinic Companion retweeted
In a first-in-human phase I study of the anti–TIGIT antibody vibostolimab as monotherapy or in combination with pembrolizumab, treatment seemed well tolerated. ORRs were 0-26%, being highest with the combination in pts with anti-PD-1/PD-L1–naïve NSCLC: annalsofoncology.org/article…
Oncology Clinic Companion retweeted
Does tumor burden impact tumor immunity and response to immunotherapy? Important review on this topic @NatRevClinOncol ow.ly/rFWA50GNIpz #JITC SM @MosheOrnsteinMD
Oncology Clinic Companion retweeted
In a randomized 1L phase 3 (eXalt3) trial in #ALK-positive #NSCLC, PFS was significantly longer with ensartinib vs crizotinib (NR vs 12.7 months, HR=0.45) by BIRC with a favorable safety profile. CNS ORR was 64% with ensartinib vs 21% with crizotinib ja.ma/3HyIUU4 #LCSM
Oncology Clinic Companion retweeted
In a phase II study of the ATR inhibitor ceralasertib plus durvalumab in pts with advanced-stage melanoma with progression on prior anti-PD-1 therapy, the ORR was 31%, the DCR was 63.3%, mPFS was 7.1 months & mOS was 14.2 months: annalsofoncology.org/article… #melsm #ImmunoOnc
Oncology Clinic Companion retweeted
New #JITC article: Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab ow.ly/NItm50GyIpC @DrBetofMDPhD @wolchokj @MPostow
Neoadjuvant PD1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal #cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial: bit.ly/3GlAQ8p
Oncology Clinic Companion retweeted
📣Today we share #Review "Overview of Immune Checkpoint Inhibitors Therapy for #Hepatocellular #Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice"
Find Full-Text on👉mdpi.com/2072-6694/11/11/168…
The Use of #Mobile Applications for the Diagnosis and Treatment of Tumors in Orthopaedic #Oncology – a #SystematicReview: bit.ly/3lIymbR #cancer #Orthopaedics
Oncology Clinic Companion retweeted
In a phase III trial in 982 men with androgen signalling inhibitor-naive mCRPC, adding apalutamide to abiraterone–prednisone improved rPFS (median 24 vs 16.6 months; HR 0.70; P<00001), but not mOS (36.2 vs 33.7 months; HR 0.95; P=0.50): thelancet.com/journals/lanon… #PCSM #uroonc
Oncology Clinic Companion retweeted
Cancer programs with high use of neoadjuvant chemotherapy for patients with advanced ovarian cancer achieve similar gains median survival and lager improvements in short-term mortality compared with programs with low use ja.ma/3F3NMPz #GynCSM
Oncology Clinic Companion retweeted
New #JITC article: Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach ow.ly/cs8t50GlzlN @TomasNeilan
Oncology Clinic Companion retweeted
Grade 2 is the grey zone for treatment decisions in early #BreastCancer . Could the development of a model using deep learning allow an improved risk stratification?
Check out this #openaccess article in @Annals_Oncology:
annalsofoncology.org/article…
#bcsm @rantalainen @ki_meb_biostat
Therapeutic drug monitoring in #oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for #imatinib therapy: bit.ly/3FiN2WO @IATDMCT @OncologyAdvance #cancer #guidelines #MedTwitter #healthcare #medicine
Access to #cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional #survey: bit.ly/3EX6Z5A #oncology #medicine #treatment #MedTwitter @TheLancetOncol
Oncology Clinic Companion retweeted
Results from the STIMULI trial by @peters_solange, @MartinReck2, and colleagues are now online in @Annals_Oncology.
Results showed no improvement for PFS & OS with nivolumab-ipilimumab consolidation after chemo-radiotherapy in limited disease #SCLC
➡️ bit.ly/3zL3ACR
Oncology Clinic Companion retweeted
#ESMOasiaweek21: registration is open & free of charge! A week of top events ✅ ESMO Asia Highlights of the Year Meeting ✅ Pan Asian adapted Guidelines lectures ✅Policy sessions ✅ #VirtualPlenary sessions ✅ Preceptorship courses 👉ow.ly/fCjq50Gfzuj
Oncology Clinic Companion retweeted
Study found ivosidenib is well tolerated and resulted in a favorable OS benefit vs placebo in advanced IDH1mutated cholangiocarcinoma, revealing a compelling clinical benefit of ivosidenib in this clinical setting ja.ma/39wefXz #GICSM
Oncology Clinic Companion retweeted
Cohort study of 634 patients w metastatic #ProstateCancer showed distinct molecular patterns assoc'd w luminal & basal subtypes, & subtypes were prognostic, with stronger benefit from androgen inhibitor therapies in pts w luminal subtype ja.ma/2W4k4IA #PCSM
Oncology Clinic Companion retweeted
Study found ivosidenib is well tolerated and resulted in a favorable OS benefit vs placebo in advanced IDH1mutated cholangiocarcinoma, revealing a compelling clinical benefit of ivosidenib in this clinical setting ja.ma/3i2yJvD #GICSM
